ATE96844T1 - Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression. - Google Patents

Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression.

Info

Publication number
ATE96844T1
ATE96844T1 AT89105110T AT89105110T ATE96844T1 AT E96844 T1 ATE96844 T1 AT E96844T1 AT 89105110 T AT89105110 T AT 89105110T AT 89105110 T AT89105110 T AT 89105110T AT E96844 T1 ATE96844 T1 AT E96844T1
Authority
AT
Austria
Prior art keywords
angiogenin
proteins
mutant
activity
angiogenic
Prior art date
Application number
AT89105110T
Other languages
German (de)
English (en)
Inventor
Jeffrey W Harper
Bert L Vallee
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE96844T1 publication Critical patent/ATE96844T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/515Angiogenesic factors; Angiogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT89105110T 1988-03-28 1989-03-22 Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression. ATE96844T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/173,760 US4900673A (en) 1988-03-28 1988-03-28 Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
EP89105110A EP0335243B1 (en) 1988-03-28 1989-03-22 Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression

Publications (1)

Publication Number Publication Date
ATE96844T1 true ATE96844T1 (de) 1993-11-15

Family

ID=22633370

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89105110T ATE96844T1 (de) 1988-03-28 1989-03-22 Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression.

Country Status (13)

Country Link
US (1) US4900673A (ja)
EP (1) EP0335243B1 (ja)
JP (1) JPH03503641A (ja)
KR (1) KR900700609A (ja)
AT (1) ATE96844T1 (ja)
AU (1) AU621358B2 (ja)
CA (1) CA1331356C (ja)
DE (1) DE68910354T2 (ja)
DK (1) DK233390A (ja)
IE (1) IE890954L (ja)
PT (1) PT90129A (ja)
WO (1) WO1989009277A1 (ja)
ZA (1) ZA892270B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520914A (en) * 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
ZA909633B (en) * 1990-02-15 1991-10-30 Harvard College Covalent angiogenin/rnase hybrids
DE4309391C2 (de) * 1993-03-23 1996-10-24 Harald Prof Dr Tschesche Verwendung von Angiogenin und/oder dessen Fragmenten als Wirkstoff zur Verhinderung oder Begrenzung der Sekretion von Proteinen aus Leukozyten
WO2001019987A1 (en) * 1999-09-13 2001-03-22 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000032221A2 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
AU721034B2 (en) 1996-02-15 2000-06-22 Biosense, Inc. Catheter based surgery
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
WO2001040464A1 (en) * 1999-11-30 2001-06-07 Genentech, Inc. Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization
US5852001A (en) * 1996-12-23 1998-12-22 The Endowment For Research In Human Biology Method and compounds for inhibition of ribonucleases
WO2000053752A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US6211157B1 (en) 1998-05-01 2001-04-03 Sulzer Biologics, Inc. Protein mixtures to induce therapeutic angiogenesis
KR20010085792A (ko) * 1998-09-14 2001-09-07 제넨테크, 인크. 혈관형성 및 심혈관형성의 촉진 또는 억제
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
EP1734051A3 (en) * 1998-12-01 2007-09-12 Genetech, Inc. Composition and methods for the diagnosis of tumours
AU2600800A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
KR100553300B1 (ko) * 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
US6794159B1 (en) * 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
JP4297317B2 (ja) * 1999-06-02 2009-07-15 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
EP1309620A2 (en) * 2000-06-23 2003-05-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
WO2004106491A2 (en) * 2003-05-22 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Angiogenin-based hiv-1 therapies
GB0425625D0 (en) 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US8828698B2 (en) * 2007-04-12 2014-09-09 Naidu Lp Immobilized angiogenin mixtures and uses thereof
US7601689B2 (en) 2007-04-12 2009-10-13 Naidu Lp Angiogenin complexes (ANGex) and uses thereof
US20130136727A1 (en) * 2009-11-19 2013-05-30 President And Fellows Of Harvard College Angiogenin and Variants Thereof for Treatment of Neurodegenerative Diseases
CN115947818B (zh) * 2022-10-25 2024-08-02 福州大学 一种血管生成素1突变体的设计及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
EP0226181B1 (en) * 1985-12-17 1994-06-15 Synergen, Inc. Human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis, DNA synthesis and migration
FR2623509B1 (fr) * 1987-11-19 1990-04-20 Centre Nat Rech Scient Proteine de 17 kd a action angiogenique, son procede d'isolement a partir de lait de mammiferes, compositions therapeutiques la contenant, procede de detection et/ou de dosage et reactifs immunologiques de detection et de dosage des angiogenines de mammiferes, de leurs homologues et de leurs fragments

Also Published As

Publication number Publication date
PT90129A (pt) 1989-11-10
EP0335243B1 (en) 1993-11-03
KR900700609A (ko) 1990-08-16
DK233390D0 (da) 1990-09-27
DE68910354T2 (de) 1994-03-03
DE68910354D1 (de) 1993-12-09
DK233390A (da) 1990-11-26
IE890954L (en) 1989-09-28
AU621358B2 (en) 1992-03-12
WO1989009277A1 (en) 1989-10-05
JPH03503641A (ja) 1991-08-15
ZA892270B (en) 1991-12-24
EP0335243A2 (en) 1989-10-04
EP0335243A3 (en) 1989-11-23
US4900673A (en) 1990-02-13
AU3433189A (en) 1989-10-16
CA1331356C (en) 1994-08-09

Similar Documents

Publication Publication Date Title
ATE96844T1 (de) Menschliches mutantes angiogenin (angiogenesefaktor mit ueberlegener angiogenin-aktivitaet), gene dafuer und methode zur expression.
ES2091768T3 (es) Factor neurotrofico ciliar purificado.
EP0155188A3 (en) Alpha-1-antitrypsin mutants and dna coding therefor and the production of each, and therapeutic formulations using such mutants and their preparation
ATE117375T1 (de) Transduktionsveränderte fibroblasten und ihre anwendung.
EP0375724A4 (en) Biologically active bactericidal/permeability-increasing protein fragments
ATE65505T1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
ATE123060T1 (de) Tgf-beta induziertes gen und protein.
AR018603A1 (es) Un peptido, util para el tratamiento y/o profilaxis de la enfermedad de alzheimer y el sindrome de down, las composiciones farmaceuticas y vacunas que locontienen, el uso de dicho peptido para la preparacion de las composiciones farmaceuticas, una secuencia de aislado de adn, un plasmido o vector vi
CA2066204A1 (en) Cystic fibrosis gene
DE3751269D1 (de) Expression des biologisch aktiven Faktors XIII.
ATE167701T1 (de) Human-nervenwachstumsfaktor
DK91389D0 (da) Kallikreiner, deres fremstilling og laegemidler indeholdende polypeptiderne
DE69117123D1 (de) Menschliches MK Gen und Protein-Sequenz
IL80562A0 (en) Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
DK587488D0 (da) Fibroblast-vaekstfaktor, nucleotidsekvens kodende derfor, praeparat indeholdende faktoren og fremgangsmaade til fremstilling deraf
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ATE230025T1 (de) Proteinanaloge des ldl-rezeptors und deren kodierende gene
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
BR1100940A (pt) Polipeptìdeos puros, sequências adn, molécula adn recombinada, célula hospedeira, processo de manipulação genética para produção de polipeptìdeo, e, uso de um polipeptìdeo
DE3878296D1 (de) Rekombinante menschliche glutathionperoxidase, verfahren zur herstellung des enzyms und dafuer kodierende dna.
ZA887950B (en) Human t-pa(u-pa)substitution-mutant proteins,recombinant dna coding therefor,transfected host cells,preparation of the mutant proteins,and pharmaceutical compositions
ATE75485T1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
ATE84315T1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties